Amgen Inc
AMGN
NASDAQ
Biotechnology
$415.21
USD
-2.63 (-0.63%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $225.90B
Volume 1.7M
Revenue
$38.09B
TTM
+9.1%
YoY
Gross Margin
70%
TTM
+7.8%
YoY
Net Income
$8.74B
TTM
+32.1%
YoY
Operating Cash Flow
$12.48B
TTM
+3.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 9,179.0 | 9,557.0 | 9,866.0 | 8,618.0 | 10,054.0 |
YoY Growth | +9.4% | +12.4% | +8.6% | +5.8% | +9.5% |
Cost of Revenue | 3,011.0 | 3,082.0 | 2,976.0 | 2,744.0 | 2,811.0 |
Gross Profit | 6,168.0 | 6,475.0 | 6,890.0 | 5,874.0 | 7,243.0 |
Selling, General & Administrative | 1,691.0 | 1,720.0 | 1,952.0 | 1,602.0 | 1,745.0 |
Other Operating Expenses | 77.0 | 329.0 | 76.0 | -113.0 | 116.0 |
Total Operating Expenses | 3,512.0 | 3,949.0 | 4,170.0 | 3,208.0 | 3,729.0 |
Operating Income | 2,656.0 | 2,526.0 | 2,720.0 | 2,666.0 | 3,514.0 |
EBITDA | 3,997.0 | 3,833.0 | 3,852.0 | 3,782.0 | 4,626.0 |
Other Income / Expense | -394.0 | 2,080.0 | -553.0 | 75.0 | -73.0 |
Total Other Income / Expense | -1,088.0 | 1,395.0 | -1,206.0 | -582.0 | -746.0 |
Income Before Income Taxes | 1,568.0 | 3,921.0 | 1,514.0 | 2,084.0 | 2,768.0 |
Income Taxes | 136.0 | 705.0 | 181.0 | 265.0 | 393.0 |
Net Income | 1,432.0 | 3,216.0 | 1,333.0 | 1,819.0 | 2,375.0 |
Consolidated Net Income / Loss | 1,432.0 | 3,216.0 | 1,333.0 | 1,819.0 | 2,375.0 |
Net Income Attributable to Common Shareholders | 1,432.0 | 3,216.0 | 1,333.0 | 1,819.0 | 2,375.0 |
Basic EPS | $2.66 | $5.98 | $2.48 | $3.37 | $4.40 |
Diluted EPS | $2.65 | $5.93 | $2.45 | $3.34 | $4.37 |
Basic Shares Outstanding | 538.0M | 538.0M | 538.0M | 540.0M | 540.0M |
Diluted Shares Outstanding | 541.0M | 542.0M | 544.0M | 544.0M | 544.0M |